The treatment of metabolic dysfunction-associated steatohepatitis (MASH) has proven challenging, with many compounds failing during development for various reasons. However, with the recent ...

In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Gift Nifty was trading around 25,085 level, a discount of nearly 35 points from the Nifty futures’ previous close, indicating ...

A medicine hailed as a “lifesaver” during the pandemic for at-risk people who caught Covid-19 should no longer be prescribed, ...

Gritstone Bio announced it is “taking action” to “preserve value and strengthen capital structure” on Thursday.

Wall Street's main indices closed lower on Thursday as investors looked to higher-than-expected inflation and unemployment ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

On today's episode of Market Domination Overtime, hosts Julie Hyman and Josh Lipton delve into the top stories following ...

Itovebi — also known as inavolisib — is designed to be given with drugs from Pfizer Inc. and AstraZeneca plc to treat adults ...

There was some intriguing news from a Pfizer (NYSE: PFE) shareholder on Thursday that was not taken well by the market.

Stocks declined on Thursday, with the S&P 500 and Dow Jones Industrial Average retreating from record highs amid signs of persistent inflation.